These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 19109437)

  • 21. The Conformational Transition Pathways and Hidden Intermediates in DFG-Flip Process of c-Met Kinase Revealed by Metadynamics Simulations.
    Jiang T; Liu Z; Liu W; Chen J; Zheng Z; Duan M
    J Chem Inf Model; 2022 Aug; 62(15):3651-3663. PubMed ID: 35848778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting inactive conformations of protein kinases using active structures: conformational selection of type-II inhibitors.
    Xu M; Yu L; Wan B; Yu L; Huang Q
    PLoS One; 2011; 6(7):e22644. PubMed ID: 21818358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
    Nagar B; Bornmann WG; Pellicena P; Schindler T; Veach DR; Miller WT; Clarkson B; Kuriyan J
    Cancer Res; 2002 Aug; 62(15):4236-43. PubMed ID: 12154025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting Mutation-Induced Allosteric Changes in Structures and Conformational Ensembles of the ABL Kinase Using AlphaFold2 Adaptations with Alanine Sequence Scanning.
    Raisinghani N; Alshahrani M; Gupta G; Verkhivker G
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states.
    Lake EW; Muretta JM; Thompson AR; Rasmussen DM; Majumdar A; Faber EB; Ruff EF; Thomas DD; Levinson NM
    Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E11894-E11903. PubMed ID: 30518564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.
    Fabbro D; Manley PW; Jahnke W; Liebetanz J; Szyttenholm A; Fendrich G; Strauss A; Zhang J; Gray NS; Adrian F; Warmuth M; Pelle X; Grotzfeld R; Berst F; Marzinzik A; Cowan-Jacob SW; Furet P; Mestan J
    Biochim Biophys Acta; 2010 Mar; 1804(3):454-62. PubMed ID: 20152788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
    Azam M; Nardi V; Shakespeare WC; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Sliz P; Veach DR; Bornmann WG; Clarkson B; Dalgarno DC; Sawyer TK; Daley GQ
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9244-9. PubMed ID: 16754879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
    Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
    Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perspective on computational and structural aspects of kinase discovery from IPK2014.
    Martin E; Knapp S; Engh RA; Moebitz H; Varin T; Roux B; Meiler J; Berdini V; Baumann A; Vieth M
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1595-604. PubMed ID: 25861861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting the Conformational Variability of Abl Tyrosine Kinase using Molecular Dynamics Simulations and Markov State Models.
    Meng Y; Gao C; Clawson DK; Atwell S; Russell M; Vieth M; Roux B
    J Chem Theory Comput; 2018 May; 14(5):2721-2732. PubMed ID: 29474075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A myristoyl/phosphotyrosine switch regulates c-Abl.
    Hantschel O; Nagar B; Guettler S; Kretzschmar J; Dorey K; Kuriyan J; Superti-Furga G
    Cell; 2003 Mar; 112(6):845-57. PubMed ID: 12654250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular mechanism of D816X mutation-induced c-Kit activation and -mediated inhibitor resistance in gastrointestinal stromal tumor.
    Jiang H; Shao W; Wang Y; Xu R; Zhou L; Mu X
    J Mol Graph Model; 2018 Sep; 84():189-196. PubMed ID: 30015051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insights into MAPK p38alpha DFG flip mechanism by accelerated molecular dynamics.
    Filomia F; De Rienzo F; Menziani MC
    Bioorg Med Chem; 2010 Sep; 18(18):6805-12. PubMed ID: 20724167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conformational disturbance in Abl kinase upon mutation and deregulation.
    Iacob RE; Pene-Dumitrescu T; Zhang J; Gray NS; Smithgall TE; Engen JR
    Proc Natl Acad Sci U S A; 2009 Feb; 106(5):1386-91. PubMed ID: 19164531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural Characterization of the Aurora Kinase B "DFG-flip" Using Metadynamics.
    Lakkaniga NR; Balasubramaniam M; Zhang S; Frett B; Li HY
    AAPS J; 2019 Dec; 22(1):14. PubMed ID: 31853739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase.
    Dorey K; Engen JR; Kretzschmar J; Wilm M; Neubauer G; Schindler T; Superti-Furga G
    Oncogene; 2001 Dec; 20(56):8075-84. PubMed ID: 11781820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular insight into mutation-induced conformational change in metastasic bowel cancer BRAF kinase domain and its implications for selective inhibitor design.
    Zhao K; Zhou X; Ding M
    J Mol Graph Model; 2018 Jan; 79():59-64. PubMed ID: 29145034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding kinase selectivity through energetic analysis of binding site waters.
    Robinson DD; Sherman W; Farid R
    ChemMedChem; 2010 Apr; 5(4):618-27. PubMed ID: 20183853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
    Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
    J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.
    Healy EF; Johnson S; Hauser CR; King PJ
    FEBS Lett; 2009 Sep; 583(17):2899-906. PubMed ID: 19660459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.